Cholestyramine cholesterol lowering intervention

Description Results NMA

all cause deaths 0.72 [0.24; 2.18]

coronary deaths 0.85 [0.27; 2.64]

non cardiovascular death 0.00 [0.00; NaN]

all cause deaths 0.95 [0.69; 1.32]

coronary deaths 0.79 [0.49; 1.26]

coronary events 0.83 [0.67; 1.01]

décès par cancer 1.06 [0.53; 2.14]

MI non fatal 0.82 [0.66; 1.03]

non cardiovascular death 1.15 [0.72; 1.82]

all cause deaths 0.00 [0.00; NaN]

cardiac death 0.00 [0.00; NaN]

non cardiovascular death NaN [NaN; NaN]

cholestyramine (n=71)

vs.

placebo (n=72)

double blind

Parallel groups

Sample size: 71/72

Primary endpoint: not defined

FU duration: 5.0 y

cholestyramine 24 g daily (n=1906)

vs.

placebo (n=1900)

double blind

Parallel groups

Sample size: 1906/1900

Primary endpoint: definite CHD death, MI

FU duration: 7.4 years

cholestyramine (n=30)

vs.

diet (n=30)

Sample size: 30/30

Primary endpoint:

FU duration: 3 years